Japan Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position
×

Sign up to download the Japan Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

Japan Pharmaceuticals & Healthcare Report
Product Price
$1,295.00

BMI View: There will be opportunities for haemophilia products within the Japan pharmaceutical market. The country has the third largest population of haemophilia patients in Asia, high levels of adherence and an extensive health insurance coverage that significantly lowers financial barriers to high-value treatments. Correspondingly, these factors have seen high levels of company activity in Japan, which will demand that firms offer differentiated treatments to effectively compete in the country.

Headline Expenditure Projections

  • Pharmaceuticals: JPY11.5trn (USD94.9bn) in 2015 to JPY11.7trn (USD101.6bn) by 2016 with a y-o-y growth of 2.2% in local currency terms and -7.1% in USD terms. Forecast unchanged from last quarter.

  • Healthcare: JPY50trn (USD419bn) in 2015 to JPY51trn (USD461bn) in 2016 with a y-o-y growth of 1.8% in local currency terms and 10% in USD terms. Forecast revised downwards due to new data from the World Health Organization. The US dollar amount remains volatile and will be contingent on the Bank of Japan's decision to weaken the currency having recently implemented negative interest rates.

Headline Pharmaceuticals & Healthcare Forecasts (Japan 2014-2020)
2014 2015 2016f 2017f 2018f 2019f 2020f
f = BMI forecast. Source: Pharmaceuticals and Medical Devices Agency (PDMA), Japan Self-Medication Industry (JSMI), The Association of the European Self-Medication Industry (AESGP), local companies, BMI
Pharmaceutical sales, USDbn 106.160 94.930 104.800 105.990 107.670 109.350 111.000
Pharmaceutical sales, % of GDP 2.31 2.30 2.33 2.32 2.30 2.27 2.24
Pharmaceutical sales, % of health expenditure 22.5 22.6 22.7 22.8 22.9 22.9 23.0
Health spending, USDbn 470.980 419.390 461.330 464.970 470.980 477.070 483.260

Risk/Reward Index

Japan continues to be ranked as the most attractive country in the region according to our Pharmaceutical Risk/Reward Index (RRI), scoring 79.4 out of 100 in Q316, significantly ahead of peers such as Australia (64.8) and South Korea (65.2) as well as the region's average at 52.3. This is driven by the country's high market expenditure scoring (18.0 out of 20.0) as well as a high spending per capita score of (12 out of 12.0). However, dragging down the country's score includes a declining population (population growth score of 1.0 out of 5.0).

Latest Updates

  • In April 2016, local news sources reported that the Liberal Democratic Party (LDP) is considering splitting up the Ministry of Health, Labor and Welfare. This was a view noted by Keiichiro Tachibana, the LDP House of Representatives lawmaker who heads a subcommittee on economic and fiscal visions for the post 2020 era.

  • That same month, Sun Pharmaceutical announced the acquisition of 14 established prescription brands from Novartis for USD 293mn. Under the terms of agreement, the acquired brands will be marketed by a local marketing partner under the Sun Pharmaceutical label.

  • Several multinational pharmaceutical firms noted that they could cut research spending in Japan due to new rules requiring a reduction in the prices of top-selling pharmaceuticals. Patrick Johnson, Chief Executive of Eli Lilly in Japan, noted that 'without stability and predictability in drug prices, investments will go elsewhere'.

BMI Economic View

We remain convinced that the Bank of Japan and the government's inflationary policies are compounding the woes of the economy, rather than improving the growth outlook, and that there is little likelihood of these policies being pared back anytime soon. As such, a sustainable recovery is a long way off, and we caution that the weakness may be only just beginning.

BMI Political View

The merger of the opposition Democratic Party of Japan (DPJ) with the smaller Japan Innovation Party (JIP) to form the Democratic Party on March 26 poses a medium-term threat to the ruling Liberal Democratic Party (LDP). Despite the Democratic Party's lack of popular support at present, they could be set to capitalise on growing frustration with the LDP's economic stewardship.

BMI Industry View
7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Japan 2013-2019)
7
SWOT
9
Industry Forecast
11
Pharmaceutical Market Forecast
11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Japan 2011-2019)
13
Healthcare Market Forecast
14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Japan 2011-2019)
16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Japan 2011-2019)
17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Japan 2011-2019)
17
Prescription Drug Market Forecast
18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Japan 2011-2019)
19
Patented Drug Market Forecast
20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Japan 2011-2019)
21
Generic Drug Market Forecast
22
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Japan 2011-2019)
24
OTC Medicine Market Forecast
25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Japan 2011-2019)
27
Pharmaceutical Trade Forecast
28
Table: Pharmaceutical Trade Data And Forecasts (Japan 2013-2019)
29
Table: Pharmaceutical Trade Data And Forecasts local currency (Japan 2013-2019)
30
Industry Risk Reward Index
31
Asia Pacific Risk/Reward Index
31
Japan Risk/Reward Index
38
Rewards
38
Risks
38
Regulatory Review
40
Regulatory Development
40
Table: OTC Drug Categories In Japan
43
Table: Prescription-To-OTC Switches In Japan (2000-2012)
44
Pricing & Reimbursement
47
Table: NCEs Approved by Origin, 2000-2010
48
Table: Timeline Of NHI Drug List Price Cuts In Japan, 1992-2010
48
Market Overview
50
Healthcare Sector
50
Table: Healthcare Resources (Japan 2009-2014)
51
Table: Healthcare Personnel (Japan 2009-2014)
52
Table: Healthcare Activity (Japan 2009-2014)
52
Research & Development
52
Clinical Trials
53
Epidemiology
54
Table: Estimated Number Of New Cases Of Cancer In Japan
56
Table: Japan: Dementia Cases And Types Across Different Areas
57
Competitive Landscape
59
Research-Based Industry
59
Table: Companies Represented By The JPMA
59
Table: Multinational Pharmaceutical Firm Activity
61
Generic Drug Industry
62
Table: Members Of The Japan Generic Medicines Association
63
Pharmaceutical Distribution
63
Pharmaceutical Retail Sector
65
Company Profile
66
Astellas
66
AstraZeneca
71
Daiichi Sankyo
74
Eisai
78
GlaxoSmithKline
84
Merck & Co
88
Mitsubishi Tanabe
91
Novartis
94
Pfizer
99
Sanofi
103
Sawai Pharmaceutical
106
Takeda Pharmaceutical Company
109
Demographic Forecast
114
Demographic Outlook
114
Table: Population Headline Indicators (Japan 1990-2025)
115
Table: Key Population Ratios (Japan 1990-2025)
115
Table: Urban/Rural Population & Life Expectancy (Japan 1990-2025)
116
Table: Population By Age Group (Japan 1990-2025)
116
Table: Population By Age Group % (Japan 1990-2025)
117
Glossary
119
Methodology
121
Pharmaceutical Expenditure Forecast Model
121
Healthcare Expenditure Forecast Model
121
Notes On Methodology
122
Risk/Reward Index Methodology
123
Index Overview
124
Table: Pharmaceutical Risk/Reward Index Indicators
124
Indicator Weightings
125

The Japan Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Japan Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Japan pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Japan, to test other views - a key input for successful budgeting and strategic business planning in the Japanese pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Japanese pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Japan.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.